Which COVID-19 vaccine should I get?

Should I try and get an mRNA vaccine? They are better than the others, aren’t they? If I show up at the clinic can I choose?

 These are some of the questions that we didn’t even know we would be so lucky to ask just three months ago. 

The speed at which multiple vaccines to choose from has come about is unprecedented. 

The first genome sequence of a previously unknown virus was published in early January 2020 and the Pfizer and Moderna mRNA vaccines, tested over the summer and fall of 2020, were approved for emergency use in early December. 

These are the quickest vaccines ever developed. Their very speed has raised a lot of questions around their safety. It is true that all previous vaccines have taken years to develop and the cumulative experience of their use over time is reassuring. 

Moderate reactions

Nevertheless the COVID-19 vaccines have been tested in very big trials. As a comparison, the widely used and “uncontroversial” Shingrix vaccine for prevention of shingles was tested in 32,000 participants prior to submission for approval in 2017. The total number of patients in COVID-19 vaccine trials that have reported results so far is 170,000 and growing rapidly. 

The safety results have been reassuring — both in the trial participants and now in millions of people worldwide who have been vaccinated and reported to national monitoring systems. 

Rates of severe side effects, mainly anaphylaxis, have been very rare — a handful in every million vaccinated — and the more common reactions such as arm pain, fever, fatigue and muscle aches have been over very quickly. 

The brief discomfort of COVID-19 vaccines seems to be greater than for the annual flu shot. This probably reflects a combination of both the “prime-boost” two-shot strategy to provoke maximum stimulation of the immune system; and the large group of vaccinees who were recently infected naturally with SARS-CoV-2 and already have a naturally primed immune system ready to react. Maybe the single-shot Johnson & Johnson vaccine will have fewer reactions?

Don’t compare
the numbers

There are now three vaccines available in the USA (Pfizer, Moderna and Johnson & Johnson) and several more globally, with more to come. 

Inevitable comparisons between the different vaccines, using their “headline” efficacy numbers, is a favorite media story at the moment. This has stimulated “vaccine shopping,” which has reached damaging levels in places like Germany, where the UK Astra-Zeneca vaccine sits un-used in warehouses whilst people wait, unprotected, for the Pfizer vaccine. 

The efficacy numbers attached to the two shots is responsible for this: 95% for Pfizer versus 62% for Astra-Zeneca. 

These numbers are a snapshot in time and can’t be compared with each other. 

Different vaccine trials

The Pfizer number was generated from a trial mainly in the USA, where most of the patients were recruited in the summer and fall of 2020. 

The Astra-Zeneca number was reported from a trial that included a substantial mixture of patients from the UK, South Africa and Brazil. 

The Pfizer and Moderna trials closely adhered to the three- or four-week interval between doses, whereas the Astra-Zeneca trial had a less strict timing. 

The different trials measured infection and symptoms in different ways at different time points. 

In more recent trials — for example the Johnson & Johnson and Novavax trials — there were large numbers of infections with new virus variants included as well. 

The efficacy result of each trial is reflective of the performance of the vaccine WITHIN that trial compared with a placebo — but not comparable OUTSIDE of the trial with the other vaccines.

Real-world results

To emphasize this, we have recent large-scale program results from the Scottish National Health Service. 

The Astra-Zeneca vaccine has been 94% effective in reducing hospitalizations so far compared with the Pfizer vaccine, which has been 85% effective. 

This reversal of efficacy rankings in a real-world observation simply emphasizes that both vaccines are great. 

The most important number of all to remember is that in the thousands and thousands of trial participants who received any of the vaccines there were no COVID deaths and almost no hospitalizations for COVID.

So when you have finally managed to find your vaccine appointment after refreshing the sign-up page a hundred times and been booked four weeks hence, don’t worry about which vaccine you will get. Just pick the one with the smallest needle.

 

James Shepherd, MD PhD, lives in Sharon, Conn., and is an Infectious Disease physician and epidemiologist who is on the faculty of the Yale University School of Medicine.

Latest News

Robert J. Pallone

NORFOLK — Robert J. Pallone, 69, of Perkins St. passed away April 12, 2024, at St. Vincent Medical Center. He was a loving, eccentric CPA. He was kind and compassionate. If you ever needed anything, Bob would be right there. He touched many lives and even saved one.

Bob was born Feb. 5, 1955 in Torrington, the son of the late Joesph and Elizabeth Pallone.

Keep ReadingShow less
The artistic life of Joelle Sander

"Flowers" by the late artist and writer Joelle Sander.

Cornwall Library

The Cornwall Library unveiled its latest art exhibition, “Live It Up!,” showcasing the work of the late West Cornwall resident Joelle Sander on Saturday, April 13. The twenty works on canvas on display were curated in partnership with the library with the help of her son, Jason Sander, from the collection of paintings she left behind to him. Clearly enamored with nature in all its seasons, Sander, who split time between her home in New York City and her country house in Litchfield County, took inspiration from the distinctive white bark trunks of the area’s many birch trees, the swirling snow of Connecticut’s wintery woods, and even the scenic view of the Audubon in Sharon. The sole painting to depict fauna is a melancholy near-abstract outline of a cow, rootless in a miasma haze of plum and Persian blue paint. Her most prominently displayed painting, “Flowers,” effectively builds up layers of paint so that her flurry of petals takes on a three-dimensional texture in their rough application, reminiscent of another Cornwall artist, Don Bracken.

Keep ReadingShow less
A Seder to savor in Sheffield

Rabbi Zach Fredman

Zivar Amrami

On April 23, Race Brook Lodge in Sheffield will host “Feast of Mystics,” a Passover Seder that promises to provide ecstasy for the senses.

“’The Feast of Mystics’ was a title we used for events back when I was running The New Shul,” said Rabbi Zach Fredman of his time at the independent creative community in the West Village in New York City.

Keep ReadingShow less
Art scholarship now honors HVRHS teacher Warren Prindle

Warren Prindle

Patrick L. Sullivan

Legendary American artist Jasper Johns, perhaps best known for his encaustic depictions of the U.S. flag, formed the Foundation for Contemporary Arts in 1963, operating the volunteer-run foundation in his New York City artist studio with the help of his co-founder, the late American composer and music theorist John Cage. Although Johns stepped down from his chair position in 2015, today the Foundation for Community Arts continues its pledge to sponsor emerging artists, with one of its exemplary honors being an $80 thousand dollar scholarship given to a graduating senior from Housatonic Valley Regional High School who is continuing his or her visual arts education on a college level. The award, first established in 2004, is distributed in annual amounts of $20,000 for four years of university education.

In 2024, the Contemporary Visual Arts Scholarship was renamed the Warren Prindle Arts Scholarship. A longtime art educator and mentor to young artists at HVRHS, Prindle announced that he will be retiring from teaching at the end of the 2023-24 school year. Recently in 2022, Prindle helped establish the school’s new Kearcher-Monsell Gallery in the library and recruited a team of student interns to help curate and exhibit shows of both student and community-based professional artists. One of Kearcher-Monsell’s early exhibitions featured the work of Theda Galvin, who was later announced as the 2023 winner of the foundation’s $80,000 scholarship. Prindle has also championed the continuation of the annual Blue and Gold juried student art show, which invites the public to both view and purchase student work in multiple mediums, including painting, photography, and sculpture.

Keep ReadingShow less